Cedars-Sinai Medical Center

University of California

The United States Government as Represented by the Department of Veterans Affairs

California Institute of Technology

Leland Stanford Junior University

Stephen Pandol

Ramachandran Murali

William A Goddard, Iii

Ravinder Abrol

Mouad Edderkaoui

Mark Menna

Aida Habtezion

Ilya Y Gukovsky

Anna Gukovskaya

The invention provides methods for treating fibrosis and/or cancer in a subject in need thereof. The methods include providing a composition comprising an inhibitor of IL-4/IL-13 receptor function and administering an effective amount of the composition to the subject to treat fibrosis and/or cancer.

Compositions and methods for treating fibrosis

The invention describes compounds that inhibit both HDAC and GSK3&#x3b2; (i.e., HDAC/GSK3&#x3b2; dual inhibitors). The invention further describes compositions containing these HDAC/GSK3&#x3b2; dual inhibitors, as well as methods and kits using these HDAC/GSK3&#x3b2; dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3&#x3b2; to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3&#x3b2;. Medical conditions treatable with various embodiments of the invention include but are not limited to cancers and tumors.

Compositions and methods for treating cancers

Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro and in vivo from cells of the GI tract of an individual.

Methods and systems for modulating hormones and related methods, agents and compositions

Provided herein are bitter taste receptor ligands, related agents, combinations, compositions, methods and systems for modulating release of a metabolic hormone in vitro or in vivo from cells of the GI tract of an individual.

Disclosed are methods of treating, preventing, modulating, attenuating, or inhibiting a disease or a disorder associated with inflammation related to NF-&#x3ba;B activation in a subject which comprises administering to the subject at least one curcumin compound. Also disclosed are combination therapies comprising the administration of at least one curcumin compound and at least one ROS inhibitor. Pharmaceutical compositions and kits are also disclosed.

Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species

Disclosed are methods for treating, preventing, or inhibiting cancer in a subject comprising administering at least one polyphenolic compound and at least one inhibitor of reactive oxygen species to the subject. The polyphenolic compound may be derived or isolated from plants. In some embodiments, the polyphenolic compound is a flavonoid. In other embodiments, the polyphenolic compound is a non-flavonoid. Other methods and kits are also disclosed as well as pharmaceutical compositions.

Growing community of inventors

Los Angeles, CA, United States of America

Stephen Pandol